Frage an Gemini
I read an editorial of Fortune Italy, in which is said , and that I knew, that even if Italy is one of the formost producers of pharmacies, the raw material for those is made in China and India. And when this delivery chain is compromised then have in Europe na problem.
Antwort Geminis
You hit the nail on the head, and that Fortune Italia editorial highlights one of the most critical, yet hidden, economic ironies in Europe today.
Italy is a absolute powerhouse in pharmaceuticals. It constantly competes with Germany as the top drug manufacturer in the European Union, boasting incredible packaging plants, high-tech logistics, and advanced clinical research. But as you rightly noted, there is a massive catch.
While Italy "bakes the cake," Asia provides the ingredients.
The "Chokehold" in the Supply Chain
The core issue lies in APIs (Active Pharmaceutical Ingredients)—the actual chemical molecules that make a drug work (like the actual paracetamol inside a tablet)—and KSMs (Key Starting Materials), which are the raw chemicals needed to make those APIs.
DrugPatentWatch
The division of labor globally looks like this:
China is the world’s undisputed king of raw chemicals and KSMs.
DrugPatentWatch
India buys those raw chemicals from China to manufacture the bulk of the world's generic APIs.
DrugPatentWatch
Italy and Europe buy those APIs to do the final formulation, safety testing, tableting, and packaging.
The Reality Check: Around 74% of the mature, commonly used active ingredients in Europe rely entirely on production lines in China or India. For essential antibiotics (like penicillin), that dependency spikes to nearly 80% to 90%.
Why did Europe let this happen?
It comes down to a brutal race to the bottom on price. For decades, European healthcare systems have faced ballooning costs, pushing national health agencies to prioritize the cheapest possible generic drugs.
Mercator Institute for China Studies (MERICS)
Because environmental regulations and labor costs are significantly lower in Asia, Chinese and Indian factories can produce APIs 30% to 40% cheaper than European facilities. European companies simply couldn't compete on price, causing local chemical synthesis plants to shut down. Just recently, major suppliers have had to close production lines in places like Brindisi because they were completely priced out by Asian competition.
Mercator Institute for China Studies (MERICS)
What happens if the chain breaks?
We don't even have to guess—we've already seen the trailer for this movie. During the COVID-19 pandemic, when China enacted strict lockdowns and cut off shipments, Europe faced immediate, severe shortages of basic antibiotics, anti-inflammatories, and painkillers.
If a true geopolitical crisis or a major trade war were to cut off the maritime routes or supply chains from China and India:
The Packaging Lines Stop: Italy’s advanced factories would run out of materials within weeks.
Critical Shortages: Hospitals and pharmacies across Europe would face severe shortages of everything from everyday fever reducers to vital cancer therapies and antibiotics.
Europe's Attempt to Fight Back
Europe is finally waking up to this vulnerability. The European Commission has launched the Critical Medicines Alliance and is pushing for a Critical Medicines Act. The goal is to bring API manufacturing back to Europe (reshoring).
Mercator Institute for China Studies (MERICS)
However, it is a massive uphill battle. Rebuilding chemical plants takes years, and unless European governments are willing to pay higher prices for locally produced medicines to offset the cost, the economic math remains incredibly difficult to fix.
It is a classic example of prioritizing short-term savings over long-term strategic security—and it's one of Europe's biggest blind spots right now.







